Intraarterial Infusion Chemotherapy with [Sar1, Ile8]Angiotensin II for Bladder Cancer

Morita, Tatsuo; Kikuchi, Takashi; Hara, Yoshinori; Ishikawa, Satoshi; Kobayashi, Yohnosuke; Ishiyama, S.; Tozuka, Katsunori; Goto, Kazumi; Takahashi, Kengo; Yoshikawa, Hideki

doi:10.1097/00000421-199206000-00002

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum samples before the treat ments and after the treatments in some cases were collected and fro zen at -80°C until analysis. Tumor stage and tumor grade were defined according to the International Union Against Cancer tumor node métastasés classification system [15], Treatments for bladder cancer consist of transurethral resection of the tumor, total cystecto my, intra-arterial infusion chemotherapy [16], and systemic chemo therapy with MV AC [17],…”

Section: Subjectsmentioning

confidence: 99%

Cytokeratin-19 Fragment (CYFRA 21-1) in Bladder Cancer

Morita

Kikuchi²,

Hashimoto³

et al. 1997

Eur Urol

Self Cite

View full text Add to dashboard Cite

Section: Subjectsmentioning

confidence: 99%

Cytokeratin-19 Fragment (CYFRA 21-1) in Bladder Cancer

Morita

Kikuchi²,

Hashimoto³

et al. 1997

Eur Urol

Self Cite

View full text Add to dashboard Cite

Serum Anti–p53 Antibodies and p53 Protein Status in the Sera and Tumors from Bladder Cancer Patients

Morita

Tachikawa²,

Kumamaru³

et al. 2000

European Urology

Self Cite

View full text Add to dashboard Cite

Effect of Adjuvant Transarterial Infusion of Anticancer Agents after Transurethral Resection in Patients with pT2a Muscle Invasive Transitional Cell Carcinoma of the Bladder: Five and Ten-year Outcome

et al. 2004

View full text Add to dashboard Cite

Five- and ten-year survival rates in patients who had transurethral resection for pT2aN0M0 muscle invasive transitional cell carcinoma of the bladder was studied with emphasis on the effect of adjuvant transarterial infusions of anticancer agents (TAI). A total of 17 patients out of 290 patients with bladder cancer who had initial treatment in our department between January 1991 and May 2001 were found to be pT2aN0M0 and were included in the present study. Fifteen patients received intravesical instillations of BCG after transurethral resection of the bladder tumor and 8 patients received TAI which was given two weeks after bacillus Calmette-Guerin therapy, with the exception of 1 patient. Five- and ten-year overall survival rates were 76.0% and 52.1%, respectively, and both five- and ten-year cancer-specific survival rates were 76.0% with an average follow up of 71 months. Significant prognostic factor associated with survival rates was only the infiltration pattern of the tumor cells between the alpha and beta group and gamma group (P = 0.0420) in cancer-specific survival rates. The data support conservative management of transurethral resection followed by intravesical instillation of BCG and TAI in patients with pT2a bladder cancer.

show abstract

Intraarterial Infusion Chemotherapy with [Sar1, Ile8]Angiotensin II for Bladder Cancer

Cited by 3 publications

References 0 publications

Cytokeratin-19 Fragment (CYFRA 21-1) in Bladder Cancer

Cytokeratin-19 Fragment (CYFRA 21-1) in Bladder Cancer

Serum Anti–p53 Antibodies and p53 Protein Status in the Sera and Tumors from Bladder Cancer Patients

Effect of Adjuvant Transarterial Infusion of Anticancer Agents after Transurethral Resection in Patients with pT2a Muscle Invasive Transitional Cell Carcinoma of the Bladder: Five and Ten-year Outcome

Contact Info

Product

Resources

About

Intraarterial Infusion Chemotherapy with [Sar1, Ile8]Angiotensin II for Bladder Cancer

Cited by 3 publications

References 0 publications

Cytokeratin-19 Fragment (CYFRA 21-1) in Bladder Cancer

Cytokeratin-19 Fragment (CYFRA 21-1) in Bladder Cancer

Serum Anti&ndash;p53 Antibodies and p53 Protein Status in the Sera and Tumors from Bladder Cancer Patients

Effect of Adjuvant Transarterial Infusion of Anticancer Agents after Transurethral Resection in Patients with pT2a Muscle Invasive Transitional Cell Carcinoma of the Bladder: Five and Ten-year Outcome

Contact Info

Product

Resources

About

Serum Anti–p53 Antibodies and p53 Protein Status in the Sera and Tumors from Bladder Cancer Patients